Fairmont Chateau Whistler Floorplan
This meeting took place in 2022
Here are the related meetings in 2024:
Inhibitory Receptors in Immune Homeostasis, Disease and Therapy (A1)
Systemic Autoimmune and Autoinflammatory Diseases (B2)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Advances in Checkpoints Immunology from Autoimmunity to Oncology to Infectious Diseases - RESCHEDULED (RB1)
Organizer(s) David M. Lee, Arlene H. Sharpe and William H. Robinson
June 8—12, 2022
Fairmont Chateau Whistler • Whistler, BC Canada
Abstract Deadline: Apr 20, 2022
Scholarship Deadline: Oct 21, 2021
Discounted Registration Deadline: Apr 7, 2022
Sponsored by AbbVie Inc., Amgen Inc., BioLegend, Inc., Genmab A/S, Infinity Pharmaceuticals, Inc., MorphoSys AG, Surface Oncology and TCR² Therapeutics
Joint Meeting:
Cancer Neoantigens, Vaccines and Viruses - RESCHEDULED (RT3)
Summary of Meeting:
Understanding of the mechanisms by which checkpoints regulate immune responses is burgeoning; molecular insights into checkpoint signaling, and complexities regarding degrees of checkpoint regulation in immune exhaustion vs. immune homeostasis are coming to light. The use of checkpoint antagonist therapeutics in Oncology has ushered in a transformation for treatment and led to major leaps in our understanding of checkpoint functions, both in health and in the context of immune responses to tumors. There are also rapidly emerging insights into the role of checkpoints in immune dysfunction seen in Autoimmune diseases, and checkpoint-targeted therapies for Autoimmune diseases are now in clinical studies. Further, treatment-associated autoimmunity syndromes comprise an important adverse event for cancer immunotherapy. While these syndromes are currently poorly understood, their analysis promises to shed new insights into improving tolerability of cancer treatment as well as into immune dysfunction in Autoimmune diseases. The meeting will provide a forum for cross-fertilization across disciplines, with a particular focus on Autoimmunity and will also include opportunities that stimulate new directions for investigation in Oncology and other diseases.
View Scholarships/Awards
Understanding of the mechanisms by which checkpoints regulate immune responses is burgeoning; molecular insights into checkpoint signaling, and complexities regarding degrees of checkpoint regulation in immune exhaustion vs. immune homeostasis are coming to light. The use of checkpoint antagonist therapeutics in Oncology has ushered in a transformation for treatment and led to major leaps in our understanding of checkpoint functions, both in health and in the context of immune responses to tumors. There are also rapidly emerging insights into the role of checkpoints in immune dysfunction seen in Autoimmune diseases, and checkpoint-targeted therapies for Autoimmune diseases are now in clinical studies. Further, treatment-associated autoimmunity syndromes comprise an important adverse event for cancer immunotherapy. While these syndromes are currently poorly understood, their analysis promises to shed new insights into improving tolerability of cancer treatment as well as into immune dysfunction in Autoimmune diseases. The meeting will provide a forum for cross-fertilization across disciplines, with a particular focus on Autoimmunity and will also include opportunities that stimulate new directions for investigation in Oncology and other diseases.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Wednesday, June 8 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Sunday, June 12 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Monday, June 13 in order to fully experience the meeting.
WEDNESDAY, JUNE 8
THURSDAY, JUNE 9
FRIDAY, JUNE 10
SATURDAY, JUNE 11
SUNDAY, JUNE 12
MONDAY, JUNE 13
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Wednesday, June 8 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Sunday, June 12 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Monday, June 13 in order to fully experience the meeting.
WEDNESDAY, JUNE 8
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address (8:00 am Start)
*
William H. Robinson,
Stanford University School of Medicine, USA
Session Chair
Session Chair
Ira Mellman,
Genentech, Inc., USA
Mechanistic Basis of Cancer Immunotherapy
Mechanistic Basis of Cancer Immunotherapy
08:00—09:00
Welcome and Keynote Address (8:00 am Start)
*
Catherine J. Wu,
Dana-Farber Cancer Institute, USA
Session Chair
Session Chair
Rafi Ahmed,
Emory University School of Medicine, USA
T Cell Functional State, from Viruses to Cancer
T Cell Functional State, from Viruses to Cancer
09:00—11:15
Advances in Checkpoint Biology I: Lymphocytes (9:00 am Start)
*
Arlene H. Sharpe,
Harvard Medical School, USA
Session Chair
Session Chair
Chen Dong,
Westlake University, School of Medicine, China
Remote Presentation: Factors that Regulate CD8+ T Cell Fates in Cancer
Remote Presentation: Factors that Regulate CD8+ T Cell Fates in Cancer
Coffee Break
Dietmar Zehn,
Technical University of Munich, Germany
Molecular Recognition of T-Cell Exhaustion
Molecular Recognition of T-Cell Exhaustion
David Bending,
University of Birmingham, UK
Short Talk: Antigen and Checkpoint Receptor Engagement Recalibrates T Cell Receptor Signal Strength
Short Talk: Antigen and Checkpoint Receptor Engagement Recalibrates T Cell Receptor Signal Strength
Joseph Jae-Suk Kim,
NYU School of Medicine, USA
Short Talk: The Role of TCR Affinity in Response to Immune Checkpoint Blockade
Short Talk: The Role of TCR Affinity in Response to Immune Checkpoint Blockade
Paolo D A Vignali,
University of Pittsburgh School of Medicine, USA
Short Talk: Tumor Hypoxia Drives Suppressor Function in Exhausted T Cells Limiting Antitumor Immunity
Short Talk: Tumor Hypoxia Drives Suppressor Function in Exhausted T Cells Limiting Antitumor Immunity
09:00—11:15
Antigen Targets (9:00 am Start)
*
Catherine J. Wu,
Dana-Farber Cancer Institute, USA
Session Chair
Session Chair
Benoît J. Van den Eynde,
University of Louvain, Belgium
The Processing of Tumor Antigens for MHC Class I Presentation to CD8 T Cells
The Processing of Tumor Antigens for MHC Class I Presentation to CD8 T Cells
Coffee Break
Michal Bassani-Sternberg,
University Hospital of Lausanne, Ludwig Institute for Cancer Research, Switzerland
Mass Spectrometry and Proteogenomics Based Approaches for Antigen Detection
Mass Spectrometry and Proteogenomics Based Approaches for Antigen Detection
Sjoerd H. van der Burg,
Leiden University Medical Center, Netherlands
Shared Neoantigens as T-Cell Targets for TAP-Impaired Tumors
Shared Neoantigens as T-Cell Targets for TAP-Impaired Tumors
Vinod Balachandran,
Memorial Sloan Kettering Cancer Center, USA
Short Talk: High Quality Neoantigens are Immunoedited in Long-Term Pancreatic Cancer Survivors
Short Talk: High Quality Neoantigens are Immunoedited in Long-Term Pancreatic Cancer Survivors
Matthew H. Bakalar,
Broad Institute, USA
Short Talk: Novel Programmable Production of pMHC Libraries with Analysis by Mass Spectrometry Enables Targeted Profiling of Peptide-MHC Binding and Stability
Short Talk: Novel Programmable Production of pMHC Libraries with Analysis by Mass Spectrometry Enables Targeted Profiling of Peptide-MHC Binding and Stability
14:30—16:30
Career Roundtable (Joint) (2:30 pm Start)
Ira Mellman,
Genentech, Inc., USA
Gulbu Uzel,
National Institutes of Health, USA
Michal Bassani-Sternberg,
University Hospital of Lausanne, Ludwig Institute for Cancer Research, Switzerland
Mishtu Dey,
Cell Press, USA
17:00—19:00
Cellular Interactions Critical to Effective Tumor Immunity (5:00 pm Start)
*
Michal Bassani-Sternberg,
University Hospital of Lausanne, Ludwig Institute for Cancer Research, Switzerland
Session Chair
Session Chair
robert david schreiber,
Washington University, USA
Remote Presentation: Spatial Proteome Analysis (CODEX) of Effective Cancer Immunotherapy
Remote Presentation: Spatial Proteome Analysis (CODEX) of Effective Cancer Immunotherapy
Jannie Borst,
Leiden University, Netherlands
How CD4+ T Cell Help Optimizes Cytotoxic T Cell Responses in Cancer
How CD4+ T Cell Help Optimizes Cytotoxic T Cell Responses in Cancer
Nir Hacohen,
Broad Institute, Massachusetts General Hospital, Harvard Medical School, USA
Spatially Organized Hubs of Immune Cells in Tumors
Spatially Organized Hubs of Immune Cells in Tumors
Giacomo Oliveira,
Dana-Farber Cancer Institute, USA
Short Talk: The Landscape of Helper and Regulatory antitumor CD4+ T cells in Human Melanoma
Short Talk: The Landscape of Helper and Regulatory antitumor CD4+ T cells in Human Melanoma
17:00—19:00
Emerging Clinical Insights into Checkpoint Contributions to Autoimmunity (5:00 pm Start)
*
William H. Robinson,
Stanford University School of Medicine, USA
Checkpoints in B Cells
Checkpoints in B Cells
*
Kevan C. Herold,
Yale University, USA
Tissue/Immune Cell Interactions Leading to Autoimmunity (Diabetes) with Checkpoint Inhibitors
Tissue/Immune Cell Interactions Leading to Autoimmunity (Diabetes) with Checkpoint Inhibitors
Alexandra-Chloé Villani,
Broad Institute of MIT and Harvard, USA
New Views on ‘Traditional' Autoimmune Disease Informed by Checkpoint Antagonist Therapy
New Views on ‘Traditional' Autoimmune Disease Informed by Checkpoint Antagonist Therapy
Ellen D. Kaan,
UMC Utrecht, Netherlands
Short Talk: Identification of Potential Immune Inhibitory Receptors in Interferon Associated Systemic Autoimmune Disease
Short Talk: Identification of Potential Immune Inhibitory Receptors in Interferon Associated Systemic Autoimmune Disease
Zoltan Maliga,
Harvard Medical School, USA
Short Talk: Molecular Characterization of Skin Toxicities from Immune Checkpoint Inhibitors
Short Talk: Molecular Characterization of Skin Toxicities from Immune Checkpoint Inhibitors
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Checkpoints in Autoimmunity: Genetic Insights and Innate Immunity Lineages(8:00 am Start)
*
Ferenc A. Scheeren,
Leiden University Medical Center, Netherlands
The Role of Glutaminyl Cyclase in Innate Immunity from Oncology to Infectious Disease
The Role of Glutaminyl Cyclase in Innate Immunity from Oncology to Infectious Disease
*
Gulbu Uzel,
National Institutes of Health, USA
Genetics 2—Insights from Human Checkpoint Mutations (both Autoimmunity and Immunodeficiency)
Genetics 2—Insights from Human Checkpoint Mutations (both Autoimmunity and Immunodeficiency)
Coffee Break
Ben A. Youngblood,
St. Jude Children's Research Hospital, USA
Epigenetic Programs Regulating CD8 T Cell Responses during Immune Checkpoint Blockade
Epigenetic Programs Regulating CD8 T Cell Responses during Immune Checkpoint Blockade
Sarah Weiss,
Harvard University, USA
Short Talk: Deletion of an Exhaustion-associated PD-1 Enhancer Augments CD8+ T cell Function in Chronic Viral Infection and Improves Tumor Control
Short Talk: Deletion of an Exhaustion-associated PD-1 Enhancer Augments CD8+ T cell Function in Chronic Viral Infection and Improves Tumor Control
Linde Meyaard,
University Medical Center Utrecht, Netherlands
Short Talk: Inhibitory Pattern Recognition Receptors as a Novel Class of Immune Regulators Recognizing Endogenous and Microbial Patterns
Short Talk: Inhibitory Pattern Recognition Receptors as a Novel Class of Immune Regulators Recognizing Endogenous and Microbial Patterns
08:00—11:00
Reprogramming the Microenvironment (8:00 am Start)
*
Kellie N. Smith,
Johns Hopkins University School of Medicine, USA
Session Chair
Session Chair
Valerie Chew,
SingHealth, Singapore
The microenvironments of Hepatitis B virus(HBV)-related Hepatocellular carcinoma
The microenvironments of Hepatitis B virus(HBV)-related Hepatocellular carcinoma
Matthew H. Spitzer,
University of California, San Francisco, USA
Talk Title to be Announced
Talk Title to be Announced
Coffee Break
Stefani Spranger,
Massachusetts Institute of Technology, USA
Not All T Cell Responses are Generated Equal: The Role of Dendritic Cells in Anti-Tumor Immunity
Not All T Cell Responses are Generated Equal: The Role of Dendritic Cells in Anti-Tumor Immunity
Abhijeet Pataskar,
Netherlands Cancer Institute, Netherlands
Short Talk: Exploring IFN-mediated Tryptophan Depletion for the Identification of Inducible Cancer Neo-antigens
Short Talk: Exploring IFN-mediated Tryptophan Depletion for the Identification of Inducible Cancer Neo-antigens
Aude-Helene Capietto,
Genentech, Inc., USA
Short Talk: Neoantigen Targeted Therapy Promotes Expansion of T Follicular Helper CD4 T Cells and Induces Rejection of Established E0771 Breast Tumors in Mice
Short Talk: Neoantigen Targeted Therapy Promotes Expansion of T Follicular Helper CD4 T Cells and Induces Rejection of Established E0771 Breast Tumors in Mice
Nicolas Cuburu,
National Cancer Institute, NIH, USA
Short Talk: Harnessing Anti-Cytomegalovirus Immunity for Local Immunotherapy against Solid Tumors
Short Talk: Harnessing Anti-Cytomegalovirus Immunity for Local Immunotherapy against Solid Tumors
Anna-Sophia Wiekmeijer,
ISA Therapeutics BV, Netherlands
Short Talk: T Cell Inducing SLP Vaccine against SARS-CoV-2 for Protection of Patients with Spontaneous or Therapy-Induced B Cell Deficiencies
Short Talk: T Cell Inducing SLP Vaccine against SARS-CoV-2 for Protection of Patients with Spontaneous or Therapy-Induced B Cell Deficiencies
14:30—16:30
Workshop 1: Emerging Checkpoints Insights: Basic and Animal Model Studies (2:30 pm Start)
*
Roarke A. Kamber,
University of California, San Francisco, USA
Systematic Discovery of Mechanisms that Impede Macrophage Phagocytosis of Cancer Cells Using Inter-cellular CRISPR Screens
Systematic Discovery of Mechanisms that Impede Macrophage Phagocytosis of Cancer Cells Using Inter-cellular CRISPR Screens
*
Hrishi Venkatesh,
University of Minnesota, USA
Targeted Therapy and Anti-PDL1 Checkpoint Blockade Elicit a CD4 T Cell Response that Eliminates B Cell Leukemia and Prevents Relapse
Targeted Therapy and Anti-PDL1 Checkpoint Blockade Elicit a CD4 T Cell Response that Eliminates B Cell Leukemia and Prevents Relapse
Michiel van der Vlist,
University Medical Center Utrecht, Netherlands
CD200R+ Macrophages Resolve Inflammatory Pain Through Interaction with iSec1 on Sensory Neurons
CD200R+ Macrophages Resolve Inflammatory Pain Through Interaction with iSec1 on Sensory Neurons
Iryna Voloshyna,
NYU School of Medicine, USA
Humanized FcγR (hFcyR) Mice as a Pre-clinical Model to Study Checkpoint Inhibitor-induced irAE
Humanized FcγR (hFcyR) Mice as a Pre-clinical Model to Study Checkpoint Inhibitor-induced irAE
Elena Fueyo-Marcos,
CNIO, Spain
Exploring the Potential of Selectively Killing PD-L1-Expressing Cells in Cancer Therapy
Exploring the Potential of Selectively Killing PD-L1-Expressing Cells in Cancer Therapy
Martina Damo,
University of Chicago, USA
Anti-PD-1 Disrupts Tolerance of Self-antigen-specific CD8 T Cells in Skin Causing Lichenoid irAEs
Anti-PD-1 Disrupts Tolerance of Self-antigen-specific CD8 T Cells in Skin Causing Lichenoid irAEs
Abby E. Overacre,
University of Pittsburgh, USA
Microbiota-specific T Follicular Helper Cells Drive Tertiary Lymphoid Structure Formation and Anti-tumor Immunity in Colorectal Cancer
Microbiota-specific T Follicular Helper Cells Drive Tertiary Lymphoid Structure Formation and Anti-tumor Immunity in Colorectal Cancer
14:30—16:30
Workshop (2:30 pm Start)
*
David A. Braun,
Dana-Farber Cancer Institute, USA
Session Chair
Session Chair
*
Giacomo Oliveira,
Dana-Farber Cancer Institute, USA
Session Chair
Session Chair
Rosaria Chila,
IFOM, The FIRC Institute of Molecular Oncology, Italy
Non-Canonical Neoantigens are the Largest Fraction of MHC I Peptides in Mismatch Repair Deficient Murine Colorectal Cancer
Non-Canonical Neoantigens are the Largest Fraction of MHC I Peptides in Mismatch Repair Deficient Murine Colorectal Cancer
Zachary C. Hartman,
Duke University, USA
Vaccination Targeting Mutant ESR1 Resistance Driver Neoepitopes to Immunologically Prevent and Suppress the Emergence of ER+ Endocrine Therapy-Resistant Breast Cancer
Vaccination Targeting Mutant ESR1 Resistance Driver Neoepitopes to Immunologically Prevent and Suppress the Emergence of ER+ Endocrine Therapy-Resistant Breast Cancer
Alex M. Jaeger,
Moffitt Cancer Center, USA
Deciphering the Immunopeptidome in vivo Reveals Novel Tumor Antigens
Deciphering the Immunopeptidome in vivo Reveals Novel Tumor Antigens
Allison M. Kirk,
St. Jude Children's Research Hospital, USA
Developing T Cell Immunotherapies Targeting Conserved Fusion Neoantigens in Fibrolamellar Carcinoma
Developing T Cell Immunotherapies Targeting Conserved Fusion Neoantigens in Fibrolamellar Carcinoma
Ana Marcu,
Genentech Inc., USA
The HLA Ligand Atlas: Defining Actionable Targets for T-Cell-Based Immunotherapy
The HLA Ligand Atlas: Defining Actionable Targets for T-Cell-Based Immunotherapy
Mark J. McCarron,
Genentech, Inc., USA
The Phenotype of the T Cell Response against Weak Antigens is Altered by the Presence of Strong T Cell Responses against Immunodominant Antigens
The Phenotype of the T Cell Response against Weak Antigens is Altered by the Presence of Strong T Cell Responses against Immunodominant Antigens
Christian Seca,
University of Liege, Belgium
Wobble tRNA Modification Regulates Melanoma Immune Response
Wobble tRNA Modification Regulates Melanoma Immune Response
Sri Krishna,
National Cancer Institute, USA
Impact of Neoantigen-Specific T Cell Phenotypes on Cellular Immunotherapies Targeting Metastatic Solid Tumors
Impact of Neoantigen-Specific T Cell Phenotypes on Cellular Immunotherapies Targeting Metastatic Solid Tumors
17:00—18:45
Advances in Checkpoint Biology II: Immune Exhaustion and Immunometabolism (5pm Start)
*
Rafi Ahmed,
Emory University School of Medicine, USA
TGF-beta Regulates the Quiescence and Differentiation of PD-1+ TCF-1+ Stem-like CD8 T Cells during Chronic Infection
TGF-beta Regulates the Quiescence and Differentiation of PD-1+ TCF-1+ Stem-like CD8 T Cells during Chronic Infection
*
Weiping Zou,
University of Michigan, USA
Metabolic Impact on Cancer Immunity and Immunotherapy
Metabolic Impact on Cancer Immunity and Immunotherapy
Christopher E. Rudd,
University of Montreal, Canada
Short Talk: Glycogen Synthase Kinase (GSK-3) Inhibition Generates CD8 Super-armed Killers in its Synergy with PD-1/PDL1 Blockade in Tumor Immunity
Short Talk: Glycogen Synthase Kinase (GSK-3) Inhibition Generates CD8 Super-armed Killers in its Synergy with PD-1/PDL1 Blockade in Tumor Immunity
Sabelo M. Lukhele,
University Health Network, Canada
Short Talk: IRF2-mediated Inhibition of Interferon Signaling Drives CD8 T Cell Exhaustion to Prevent Long-term Cancer Control
Short Talk: IRF2-mediated Inhibition of Interferon Signaling Drives CD8 T Cell Exhaustion to Prevent Long-term Cancer Control
Andrew Frisch,
University of Pittsburgh, USA
Short Talk: Redirecting Glucose Flux During In Vitro Expansion Improves the In Vivo Performance of Adoptive T Cell Therapies for Cancer
Short Talk: Redirecting Glucose Flux During In Vitro Expansion Improves the In Vivo Performance of Adoptive T Cell Therapies for Cancer
17:00—19:00
Immune Targeting against Viral Antigens (5:00 pm Start)
*
Susan E. Klaeger,
Broad Institute, USA
Session Chair
Session Chair
Helen Heslop,
Baylor College of Medicine, Houston Methodist Hospital and Texas Children's, USA
Adoptive Transfer of Virus Specific T Cells
Adoptive Transfer of Virus Specific T Cells
Cornelis J. M. Melief,
Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Vaccines Targeting HPV Antigens
Vaccines Targeting HPV Antigens
Kellie N. Smith,
Johns Hopkins University School of Medicine, USA
Discovery and Characterization of Tumor-Reactive TIL
Discovery and Characterization of Tumor-Reactive TIL
Derin Benerci Keskin,
Dana Farber Cancer Institute, USA
Short Talk: Reversal of Viral and Epigenetic HLA Class I Repression in Merkel Cell Carcinoma
Short Talk: Reversal of Viral and Epigenetic HLA Class I Repression in Merkel Cell Carcinoma
Michael C. Brown,
Duke University, USA
Short Talk: Intratumor Childhood Vaccine-specific CD4+ T Cell Recall Coordinates Antitumor Type I and II Immunity
Short Talk: Intratumor Childhood Vaccine-specific CD4+ T Cell Recall Coordinates Antitumor Type I and II Immunity
Esmé van der Gracht,
ISA Therapeutics, Netherlands
Remote Presentation: Short Talk: A Third Vaccination with a Single T Cell Epitope Protects against Lethal SARS-CoV-2 Infection
Remote Presentation: Short Talk: A Third Vaccination with a Single T Cell Epitope Protects against Lethal SARS-CoV-2 Infection
18:45—19:30
Panel Discussion: New Directions in Checkpoint Biology: Major Gaps and Emerging Insights (6:45 pm Start)
*
Arlene H. Sharpe,
Harvard Medical School, USA
Session Chair
Session Chair
Weiping Zou,
University of Michigan, USA
Jennifer Guerriero,
Brigham and Women's Hospital, USA
David A. Hafler,
Yale University School of Medicine, USA
Bali Pulendran,
Stanford University School of Medicine, USA
Ira Mellman,
Genentech, Inc., USA
19:30—20:30
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Immunoregulation and Immunosuppression (Joint) (8:00 am Start)
*
Thomas Gajewski,
University of Chicago, USA
The Tumor Microenvironment and Immunotherapy Efficacy
The Tumor Microenvironment and Immunotherapy Efficacy
Hussein Sultan,
Washington University School of Medicine, USA
Unexpected Complexity of Neoantigen Specific Synthetic Long Peptide Cancer Vaccines: Potential for Induction of Tumor Specific Immunosuppressive CD4+ T cells
Unexpected Complexity of Neoantigen Specific Synthetic Long Peptide Cancer Vaccines: Potential for Induction of Tumor Specific Immunosuppressive CD4+ T cells
Coffee Break
Jennifer Guerriero,
Brigham and Women's Hospital, USA
Elucidating Macrophage Diversity to Uncover Novel Anti-cancer Therapeutic Strategies
Elucidating Macrophage Diversity to Uncover Novel Anti-cancer Therapeutic Strategies
David A. Hafler,
Yale University School of Medicine, USA
Transcriptional Mechanism of FoxP3+ Treg Dysfunction in Human Autoimmune Disease
Transcriptional Mechanism of FoxP3+ Treg Dysfunction in Human Autoimmune Disease
Jessica Stark,
Stanford University, USA
Short Talk: Antibody-lectin Bispecifics for Glyco-immune Checkpoint Blockade
Short Talk: Antibody-lectin Bispecifics for Glyco-immune Checkpoint Blockade
Andreas Wieland,
Ohio State University, USA
Short Talk: Defining HPV-Specific B Cell Responses in Patients with Head and Neck Cancer
Short Talk: Defining HPV-Specific B Cell Responses in Patients with Head and Neck Cancer
15:00—16:30
Workshop 2: Emerging Checkpoints Insights: Translational and Clinic Studies (3:00 pm Start)
*
Kate Carbone,
Genentech, Inc., USA
Surveillance of in situ Tumor Arrays Reveals Early Environmental Control of Cancer Immunity
Surveillance of in situ Tumor Arrays Reveals Early Environmental Control of Cancer Immunity
*
Zhi Liang Chu,
Crossignal Therapeutics, Inc., USA
TMER1: A Treg Cell Expressed, Hippo-YAP Regulating GPCR as a Novel Target for Cancer Immunotherapy Drug Development
TMER1: A Treg Cell Expressed, Hippo-YAP Regulating GPCR as a Novel Target for Cancer Immunotherapy Drug Development
Jenna Lynn Collier,
Harvard University, USA
PD-1 Blockade Drives T Cell Transcriptional States in NOD Mice that are Comparable to T Cells in NOD Mice with Spontaneous Autoimmune Diabetes
PD-1 Blockade Drives T Cell Transcriptional States in NOD Mice that are Comparable to T Cells in NOD Mice with Spontaneous Autoimmune Diabetes
David R. Glass,
Fred Hutchinson Cancer Center, USA
Multi-omic Analysis of Cutaneous T Cell Lymphomas Reveals Broad Changes in Cellular Immunity Induced by Mono- and Combination Anti-PD-1 Immunotherapy
Multi-omic Analysis of Cutaneous T Cell Lymphomas Reveals Broad Changes in Cellular Immunity Induced by Mono- and Combination Anti-PD-1 Immunotherapy
Akashdip Singh,
UMC Utrecht, Netherlands
Cancer Immunotherapy by NC410, a LAIR-2 Fc Protein Blocking Human LAIR-collagen Interaction
Cancer Immunotherapy by NC410, a LAIR-2 Fc Protein Blocking Human LAIR-collagen Interaction
17:00—19:00
Checkpoints in Autoimmunity: Function and Dysfunction in Disease (5:00 pm Start)
*
Bali Pulendran,
Stanford University School of Medicine, USA
Systems Biological Analysis of Immunity to COVID-19 Infection and Vaccination
Systems Biological Analysis of Immunity to COVID-19 Infection and Vaccination
*
Eoin McKinney,
Cambridge University, UK
Lymphocyte Exhaustion State in Autoimmune Disease X: Integrating Functional Status across Active Checkpoints
Lymphocyte Exhaustion State in Autoimmune Disease X: Integrating Functional Status across Active Checkpoints
David M. Lee,
Janssen Pharmaceutical Companies of Johnson & Johnson, USA
Co-inhibitory Modulators In Autoimmunity: The Complex Path From Concept to Therapeutic Candidates
Co-inhibitory Modulators In Autoimmunity: The Complex Path From Concept to Therapeutic Candidates
Chris Paluch,
MiroBio Ltd, UK
Short Talk: A BTLA Agonist Antibody for the Treatment of Autoimmune Disease
Short Talk: A BTLA Agonist Antibody for the Treatment of Autoimmune Disease
Yang Zhao,
Janssen Immunology Discovery, USA
Short Talk: VISTA is a Checkpoint Receptor Target for Autoimmune Diseases
Short Talk: VISTA is a Checkpoint Receptor Target for Autoimmune Diseases
17:00—19:00
Combination Therapy with Oncolytic Virus and Viral Delivery Systems (5:00 pm Start)
*
Jennifer Guerriero,
Brigham and Women's Hospital, USA
Session Chair
Session Chair
Matthias Gromeier,
Duke University School of Medicine, USA
Cancer Immunotherapy through Endogenous Type-I IFN Dominant Signaling in Dendritic Cells
Cancer Immunotherapy through Endogenous Type-I IFN Dominant Signaling in Dendritic Cells
Klaus Früh,
Oregon Health & Science University, USA
Harnessing the Unique Immune Biology of Cytomegalovirus for Cancer Immunotherapy
Harnessing the Unique Immune Biology of Cytomegalovirus for Cancer Immunotherapy
E. Antonio Chiocca,
Brigham and Women's Hospital, USA
Clinical Trials of Oncolytic Virus- and Gene-based Immunotherapy: Human Evidence of Changes in the Tumor Immune Microenvironment
Clinical Trials of Oncolytic Virus- and Gene-based Immunotherapy: Human Evidence of Changes in the Tumor Immune Microenvironment
Kristin DePeaux,
University of Pittsburgh, USA
Short Talk: Overcoming Microenvironmental Resistance to Oncolytic Virus Immunotherapy with Virus-encoded Delivery of a Potent TGFß Inhibitor
Short Talk: Overcoming Microenvironmental Resistance to Oncolytic Virus Immunotherapy with Virus-encoded Delivery of a Potent TGFß Inhibitor
Emma Wagner,
University of Cambridge, UK
Short Talk: Role of Innate Immune DNA Sensing in Response to Oncolytic Virus Therapy
Short Talk: Role of Innate Immune DNA Sensing in Response to Oncolytic Virus Therapy
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Checkpoints in Oncology—Treatment Effectiveness, Include CAR T, States of Immune Exhaustion in I O, and Combo Approaches (8:00 am Start)
Maria E. Suarez-Almazor,
University of Texas MD Anderson Cancer Center, USA
Remote Presentation: Immune-related Adverse Events with Checkpoint Inhibitors'
Remote Presentation: Immune-related Adverse Events with Checkpoint Inhibitors'
*
Charles G. Drake,
Janssen, USA
Talk Title to be Announced
Talk Title to be Announced
Coffee Break
Arlene H. Sharpe,
Harvard Medical School, USA
Defining Regulators of Immunity to Infections and Tumors using in vivo CRISPR Screens
Defining Regulators of Immunity to Infections and Tumors using in vivo CRISPR Screens
Alex C. McPherson,
University of Pittsburgh, USA
Short Talk: Exploring the Mechanisms of how Commensal Bacteria Colonize Gut-distal Melanoma Tumors and Impact Immune Checkpoint Inhibitor Efficacy
Short Talk: Exploring the Mechanisms of how Commensal Bacteria Colonize Gut-distal Melanoma Tumors and Impact Immune Checkpoint Inhibitor Efficacy
Chun Wai Wong,
University of Manchester, UK
Short Talk: Inhibition of PARP14 Restores Response to Anti-PD1 Immune Checkpoint Inhibition
Short Talk: Inhibition of PARP14 Restores Response to Anti-PD1 Immune Checkpoint Inhibition
08:00—11:15
Vaccines in Cancer and Other Non Infectious Syndromes (8:00 am Start)
*
Cornelis J. M. Melief,
Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Session Chair
Session Chair
Gerald P. Linette,
University of Pennsylvania, USA
Dendritic-Based Targeting of Tumor Neoantigens
Dendritic-Based Targeting of Tumor Neoantigens
Jan David Beck,
BioNTech SE, Germany
Combining RNA-encoded Interleukin-2 with Antibodies Overcomes Resistance in MHC Class I-deficient Cancer
Combining RNA-encoded Interleukin-2 with Antibodies Overcomes Resistance in MHC Class I-deficient Cancer
Coffee Break
Catherine J. Wu,
Dana-Farber Cancer Institute, USA
SLPs for Personal Neoantigen-Targeting Vaccines
SLPs for Personal Neoantigen-Targeting Vaccines
Megan L. Burger,
Massachusetts Institute of Technology, USA
Short Talk: Antigen Dominance Hierarchies Shape Anti-tumor T Cell Phenotypes and Immunotherapy Response
Short Talk: Antigen Dominance Hierarchies Shape Anti-tumor T Cell Phenotypes and Immunotherapy Response
Ann-Jay Tong,
Genentech, Inc., USA
Short Talk: Molecular Determinants of Effective Neoantigen-specific T Cell Responses Following Vaccination
Short Talk: Molecular Determinants of Effective Neoantigen-specific T Cell Responses Following Vaccination
Anna Morena D'Alise,
Nouscom Srl, Italy
Short Talk: Viral Vectored Vaccines Targeting Tumor Neoantigens Elicit Potent and Effective Anti-tumor Immune Response
Short Talk: Viral Vectored Vaccines Targeting Tumor Neoantigens Elicit Potent and Effective Anti-tumor Immune Response
Najla Arshad,
Yale University, USA
Short Talk: Discovery of Immunogenic, Tumor-Associated Peptides Presented by Major Histocompatibility Complex Class I in a Myeloproliferative Neoplasm Cell Line
Short Talk: Discovery of Immunogenic, Tumor-Associated Peptides Presented by Major Histocompatibility Complex Class I in a Myeloproliferative Neoplasm Cell Line
David A. Braun,
Dana-Farber Cancer Institute, USA
Short Talk: A Personalized Neoantigen Vaccination Incorporating Locally Delivered Ipilimumab Induces Tumor-specific Immunity in Renal Cell Carcinoma
Short Talk: A Personalized Neoantigen Vaccination Incorporating Locally Delivered Ipilimumab Induces Tumor-specific Immunity in Renal Cell Carcinoma
17:00—18:00
Checkpoints Insights from Infectious Diseases and Environmental Triggers (5:00 pm Start)
*
Georg Lauer,
Massachusetts General Hospital, USA
Checkpoint Signaling and Phenotype in Chronic Viral Infections
Checkpoint Signaling and Phenotype in Chronic Viral Infections
*
Alice O. Kamphorst,
Icahn School of Medicine at Mount Sinai, USA
Strength of CD28 Costimulation Directs Self-Renewal and Differentiation of TCF-1+ PD-1+ CD8 T Cells
Strength of CD28 Costimulation Directs Self-Renewal and Differentiation of TCF-1+ PD-1+ CD8 T Cells
Susan E. McClory,
University of Pennsylvania/CHOP, USA
Short Talk: Trib1 Inhibits Viral-specific T Cell Responses during Chronic Infection by Promoting Terminal Exhaustion
Short Talk: Trib1 Inhibits Viral-specific T Cell Responses during Chronic Infection by Promoting Terminal Exhaustion
17:00—18:45
Novel Combinatorial Approaches (5:00 pm Start)
*
Gerald P. Linette,
University of Pennsylvania, USA
Session Chair
Session Chair
David E. Avigan,
Beth Israel Deaconess Medical Center, USA
Integrating a Personalized Cancer Vaccine with Cellular Immunotherapy
Integrating a Personalized Cancer Vaccine with Cellular Immunotherapy
Ravi Uppaluri,
BWH, USA
Neoadjuvant PD1 Therapy
Neoadjuvant PD1 Therapy
Brooke Huisman,
MIT, USA
Short Talk: Characterizing the Peptide Repertoire of HLA-E and Natural Killer Cell Receptors via Yeast Display
Short Talk: Characterizing the Peptide Repertoire of HLA-E and Natural Killer Cell Receptors via Yeast Display
Marcus Bosenberg,
Yale University, USA
Short Talk: Epigenetic Regulation of Endogenous Retroelement Expression Modulates Anti-cancer Immune Responses
Short Talk: Epigenetic Regulation of Endogenous Retroelement Expression Modulates Anti-cancer Immune Responses
Christianne Groeneveldt,
Leiden University Medical Center, Netherlands
Short Talk: Repurposing Reovirus-specific T Cells as Antitumor Effector Cells
Short Talk: Repurposing Reovirus-specific T Cells as Antitumor Effector Cells
18:00—18:45
Panel Discussion: Targeting Checkpoints in Human Disease: Gaps for Translation and Opportunities Ahead (6:00 pm Start)
*
David M. Lee,
Janssen Pharmaceutical Companies of Johnson & Johnson, USA
Session Chair
Session Chair
Alexandra-Chloé Villani,
Broad Institute of MIT and Harvard, USA
Charles G. Drake,
Janssen, USA
Georg Lauer,
Massachusetts General Hospital, USA
Alice O. Kamphorst,
Icahn School of Medicine at Mount Sinai, USA
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (7:00 pm Start)
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (6:45 pm Start)
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
We gratefully acknowledge additional support from these exhibitors at this conference:
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Josh May, Director, Technology and Digital Media, Email: joshuam@keystonesymposia.org, Phone:+1 970-262-1179 |